Alphabet's Isomorphic Labs is poised to revolutionise drug discovery as it transitions from AI research to human clinical trials. This venture, housed within Alphabet's 'Other Bets' segment, offers a speculative...
Lemonade Inc. is poised for potential revenue growth as it considers a bold strategy to slash its reinsurance quota from 55% to 20%, significantly altering its risk management approach. This...
The balance of monetary policy is facing a potential upheaval with renewed political interest in the US Federal Reserve's leadership. Recent remarks from former President Trump about not reappointing Jerome...
Protagenic Therapeutics is navigating the high-stakes world of CNS drug development, with its future resting on the success of its lead candidate, PT-00114. Recent corporate manoeuvres, such as a reverse...
NIO Inc. is navigating a challenging landscape where its record-breaking deliveries and strategic launch of the mass-market Onvo brand clash with substantial financial hurdles. While operational growth seems promising with...
Amidst Bitcoin's dynamic consolidation, the spotlight is on the audacious price target of $144,000, influenced by Elliott Wave theory. Yet, with the arrival of spot Bitcoin ETFs and their institutional...
Lion Group Holding's bold $7 million foray into digital assets, focusing on HYPE, SOL, and SUI tokens, marks a strategic pivot in their corporate treasury. Backed by a potential $600...
The 2024 resurgence of GameStop and AMC wasn't a replay of the 2021 meme stock frenzy, but rather a personality-driven event fuelled by Keith Gill's return. Despite the excitement, both...
CleanSpark's narrative isn't merely about a short squeeze but a strategic evolution in Bitcoin mining. Its financial turnaround, marked by a substantial net income, reflects a robust operational shift driven...
Zeta Global is poised for a breakout, eyeing the $19 mark, as its stock consolidates within a tight pattern. The company has shifted from a revenue-focused growth story to delivering...
